Fujirebio launches the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood tests

The new biomarker tests will allow further study of the clinical utility of NfL in diverse disease conditions

27 Mar 2023

Jessica Calvey

Product and Reviews Admin Assistant

H.U. Group Holdings Inc., and its wholly owned subsidiary Fujirebio, have announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE^® G immunoassay systems. These chemiluminescent enzyme immunoassay (CLEIA) assays allow for the quantitative measurement of neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes*.

The new biomarker tests will allow researchers and clinical research professionals to further study the clinical utility of NfL in diverse disease conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease, as well as in acute situations such as traumatic brain injury. NfL is considered a promising biomarker for disease activity, progression, prognosis, and monitoring effectiveness of therapies.

Laboratory professionals can select their preferred specimen matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This standardized immunoassay system family is widely available and used in routine labs active in the field of neurological diseases with its current assay menu. The LUMIPULSE G platform meets the necessary throughput, quality, and regulatory requirements to support possible future routine use of NfL in addition to the existing portfolio.

“In 2022, we introduced three fully automated blood-based assays for the detection of pTau₁₈₁, β-Amyloid_1-42 and β-Amyloid_1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” said Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative disease field as quickly as possible.”

*The two assays are available for research use only.